Document Type: Original Research
Department of Pathology,Yas Hospital, Tehran University of Medical Sciences,Tehran, Iran
Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Background & Objective: Endometrial carcinoma (EC) has been traditionally classified into two distinct categories of low-grade and high-grade. Type I (low grade) EC, which constitutes the majority of cases, is linked to estrogen-related molecular pathways. But type II (high-grade) EC accounts for 10-20% of cases and behaves in an aggressive way. Pathologic and biological features of type II EC have not been fully elucidated yet. Several investigations have demonstrated HER2/neu expression and amplification in type II EC, especially papillary serous carcinoma (PSC).This study assessed HER2/neu expression in high-grade EC as well as its association with other clinical and histopathological prognostic factors.
Methods: In this cross-sectional study, we performed HER2/neu immunohistochemical (IHC) staining in 37 high-grade EC cases with histological diagnostic categories of PSC (n=23), clear cell carcinoma (CCC) (n=9), and carcinosarcoma with high-grade carcinomatous component (PSC, CCC, grade 3 endometrioid carcinoma, or unclassified high-grade adenocarcinoma) (n=5). All patients were followed for 2-9 years in order to evaluate their disease-free survival (DFS) and overall survival (OS) during study period (2005-2014).
Results: HER2/neu IHC staining was positive in 12 patients (32.4%) including 8/23 (34.8%) PSC, 2/9 (22.2%) CCC, and 2/5 (40%) carcinosarcoma cases. There was no statistically significant difference between HER2/neu expression and DFS or OS of the patients (P>0.05).
Conclusion: We observed that HER2/neu is expressed in one-third of high-grade ECs. This ancillary test is supportive in follow-up of patients with high-grade ECs.
- Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, et al. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci. 2012;103(5):926-32. [DOI:10.1111 /j.1349-7006.2012.02240.x] [PMID]
- Pathiraja P, Dhar S, Haldar K. Serous endometrial intraepithelial carcinoma: a case series and literature review. Cancer Manag Res. 2013;5:117-22. [DOI:10.2147 /CMAR.S45141] [PMID] [PMCID]
- Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, et al. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol. 2013;24(2):120-7. [DOI:10.3802/jgo.2013.24.2.120] [PMID] [PMCID]
- Talwar S, Cohen S. Her-2 targeting in uterine papillary serous carcinoma. Gynecol Oncol Case Rep. 2012;2(3):94-6. [DOI:10.1016/j.gynor.2012.05.003] [PMID] [PMCID]
- Rossi ED, Bizzarro T, Monterossi G, Inzani F, Fanfani F, Scambia G, et al. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components. Hum Pathol. 2017;62:99-107. [DOI:10.1016/j.humpath.2016.12.015] [PMID]
- Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int J Gynecol Pathol. 2019;38 Suppl 1:S40-S63. [DOI:10.1097/PGP.0000000000000491] [PMID] [PMCID]
- Gatius S, Matias-Guiu X. Practical issues in the diagnosis of serous carcinoma of the endometrium. Mod Pathol. 2016;29 Suppl 1:S45-58. [DOI:10.1038/modpathol.2015.141] [PMID]
- del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127(3):651-61. [DOI:10.1016/j.ygyno.2012.09.012] [PMID]
- Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813-8. [DOI:10.1 016/j.ajog.2004.10.605] [PMID]
- Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Arch Pathol Lab Med. 2014;138(3):343-50. [DOI:10.5858/arpa.2012-0416-RA] [PMID]
- Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol. 2010;116(2):286-9. [DOI:10.1016/j.ygyno.2009.11.012] [PMID]
- English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol. 2013;131(3):753-8. [DOI:10.1016/j.ygyno.20 13.08.033] [PMID]
- Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391-7. [DOI:10.1002/c ncr.21308] [PMID]
- Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, et al. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer. 2017;140(6):1396-404. [DOI:10.1 002/ijc.30537] [PMID]
- Xiao W, Dong X, Zhao H, Han S, Nie R, Zhang X, et al. Expression of MIF and c-erbB-2 in endometrial cancer. Mol Med Rep. 2016;13(5):3828-34. [DOI:10.38 92/mmr.201 6.4992] [PMID] [PMCID]
- Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126-32. [DOI:10.120 0/JCO.2004 .11.154] [PMID]
- Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF, et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):3-9. [DOI:10.1016 /j.ygyno.20 07.09.007] [PMID] [PMCID]
- Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24(15):2376-85. [DOI:10.1200/JCO.2005.03.4827] [PMID]